Stock Research for CYTK

CYTK

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CYTK Stock Chart & Research Data

The CYTK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CYTK Due diligence Resources & Stock Charts

The CYTK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYTK Detailed Price Forecast - CNN Money CNN View CYTK Detailed Summary - Google Finance
Yahoo View CYTK Detailed Summary - Yahoo! Finance Zacks View CYTK Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CYTK Trends & Analysis - Trade-Ideas Barrons View CYTK Major Holders - Barrons
NASDAQ View CYTK Call Transcripts - NASDAQ Seeking View CYTK Breaking News & Analysis - Seeking Alpha
Spotlight View CYTK Annual Report - CompanySpotlight.com OTC Report View CYTK OTC Short Report - OTCShortReport.com
TradeKing View CYTK Fundamentals - TradeKing Charts View CYTK SEC Filings - Bar Chart
WSJ View Historical Prices for CYTK - The WSJ Morningstar View Performance/Total Return for CYTK - Morningstar
MarketWatch View the Analyst Estimates for CYTK - MarketWatch CNBC View the Earnings History for CYTK - CNBC
StockMarketWatch View the CYTK Earnings - StockMarketWatch MacroAxis View CYTK Buy or Sell Recommendations - MacroAxis
Bullish View the CYTK Bullish Patterns - American Bulls Short Pains View CYTK Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CYTK Stock Mentions - StockTwits PennyStocks View CYTK Stock Mentions - PennyStockTweets
Twitter View CYTK Stock Mentions - Twitter Invest Hub View CYTK Investment Forum News - Investor Hub
Yahoo View CYTK Stock Mentions - Yahoo! Message Board Seeking Alpha View CYTK Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CYTK - SECform4.com Insider Cow View Insider Transactions for CYTK - Insider Cow
CNBC View CYTK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYTK - OTC Markets
Yahoo View Insider Transactions for CYTK - Yahoo! Finance NASDAQ View Institutional Holdings for CYTK - NASDAQ


Stock Charts

FinViz View CYTK Stock Insight & Charts - FinViz.com StockCharts View CYTK Investment Charts - StockCharts.com
BarChart View CYTK Stock Overview & Charts - BarChart Trading View View CYTK User Generated Charts - Trading View




Latest Financial News for CYTK


Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND
Posted on Monday December 10, 2018

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 29th International Symposium on.


Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor
Posted on Wednesday December 05, 2018

Cytokinetics, Incorporated (CYTK) today announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple ascending dose clinical trial of CK-3773274 (CK-274) in healthy adult subjects. CK-274 is a novel cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM). “The start of clinical trials for CK-274 marks an important milestone in our continuing innovation of potential sarcomere-directed medicines,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development.


Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More
Posted on Monday December 03, 2018

On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he isn't a fan of Netflix, Inc. (NASDAQ: NFLX ) because the content isn't as compelling as it once was. He sees it as a good story, but ...


Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Tuesday November 27, 2018

NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.